GLUT-1 is preferentially expressed in atypical endometrial hyperplasia and endometrial adenocarcinoma

Applied Immunohistochemistry and Molecular Morphology

Volumn 14, Issue 2, 2006, Pages 187-192

  Ashton Sager, Amanda ^a   Paulino, Augusto F G ^b   Afify, Alaa M ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Genzyme Genetics   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Endometrial adenocarcinoma; Endometrial hyperplasia; GLUT 1

Indexed keywords

GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 7; MONOSACCHARIDE; UNCLASSIFIED DRUG;

ADENOMYOSIS; ARTICLE; BLOOD BRAIN BARRIER; CAPILLARY ENDOTHELIUM; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; ERYTHROCYTE; GENE EXPRESSION; GLUCOSE TRANSPORT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; PERINEURIUM; PERIPHERAL NERVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

ADENOCARCINOMA; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; FEMALE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; IMMUNOHISTOCHEMISTRY;

EID: 33745356796     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/01.pai.0000162003.43334.c7     Document Type: Article

References (50)

1. Winkler B, Alvarez S, Richart RM, et al. Pitfalls in the diagnosis of endometrial hyperplasia. Obstet Gynecol. 1984;64:185-189.
2. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia: a long-term study of "untreated" hyperplasia in 170 patients. Cancer. 1985;56:403-412.
3. Baak J, Wisse-Brekelmans E, Fleege J, et al. Assessment of the risk on endometrial cancer in hyperplasia, by means of morphological and morphometrical features. Pathol Res Pract. 1992;188:856-859.
4. Huang SJ, Amparo EG, Fu YS. Endometrial hyperplasia: histologic classification and behavior. Surg Pathol. 1988;1:215-229.
5. Skov BG, Broholm H, Engel U, et al. Comparison of the reproducibility of the WHO classifications of 1975 and 1994 of endometrial hyperplasia. Int J Gynecol Pathol. 1997;16:33-37.
6. Mueckler M. Facilitative glucose transporters. Eur J Biochem. 1994;219:713-725.
7. Bell GI, Kayano T, Buse JB, et al. Molecular biology of mammalian glucose transporters. Diabetes Care. 1990;13:198-208.
8. Gould GW, Bell GI. Facilitative glucose transporters: an expanding family. Trends Biochem Sci. 1990;15:18-23.
9. Doege H, Schurmann A, Bahrenberg G, et al. GLUT-8, a novel member of the sugar transport facilitator family with glucose transport activity. J Biol Chem Mol Biol. 2000;275:16275-16280.
10. Younes M, Lechago LV, Somoano JR, et al.Wide expression of the human erythrocyte glucose transporter GLUT-1 in human cancers. Cancer Res. 1996;56:1164-1167.
11. Froehner SC, Davies A, Baldwin SA, et al. The blood-nerve barrier is rich in glucose transporter. J Neurocytol. 1998;17:173.
12. Yoshikazu N, Aya S, Yohei M, et al. Suppression of facilitative glucose transporter 1 mRNA can suppress tumor growth. Cancer Lett. 2000;154:175-182.
13. Warburg O. The Metabolism of Tumors. New York: Richard R Smith, 1931.
14. Isselbacher KJ. Sugar and amino acid transport by cells in culture - differences between normal and malignant cells. N Engl J Med. 1972;286:929-933.
15. Yamamoto Y, Seino H, Fukumoto G, et al. Overexpression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun. 1990;170:223-230.
16. Brown RS, Leung JY, Kison PV, et al. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med. 1999;40:556-565.
17. Ito T, Noguchi Y, Satoh S, et al. Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage. Mod Pathol. 1998;11:437-443.
18. Noguchi Y, Marat D, Saito A, et al. Expression of facilitative glucose transporters in gastric tumors. Hepatogastroenterology. 1999;46:2683-2689.
19. Boado RJ, Black KL, Pardridge WM. Gene expression of GLUT3 and GLUT1 glucose transporters in human brain tumors. Brain Res Mol Brain Res. 1994;27:51-57.
20. Su TS, Tsai TF, Chi CW, et al. Elevation of facilitative glucose-transporter messenger RNA in human hepatocellular carcinoma. Hepatology. 1990;11:118-122.
21. Brown RS, Wahl RL. Overexpression of GLUT-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer. 1993;72:2979-2985.
22. Haber RS, Rathan A, Weiser RK, et al. GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer. 1998;83:34-40.
23. Kalir T, Wang BY, Goldfischer M, et al. Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia. Cancer. 2002;94:1078-1082.
24. Flier JS, Mueckler MM, Usher P, et al. Elevated levels of glucose transport and transporters messenger RNA are induced by ras or src oncogenes. Science. 1987;235:1492-1495.
25. Chen C, Pore N, Behrooz A, et al. Regulation of glut-1 mRNA by hypoxiainducible factor-1. J Biol Chem. 2001;276:9519-9525.
26. Nefesh I, Bauskin AR, Alkalay I, et al. IL-3 facilitates lymphocyte hexose transport by enhancing the intrinsic activity of the transport system. Int Immunol. 1991;3:827-831.
27. Hiraki Y, Rosen OM, Birnbaum MJ. Growth factors rapidly induce expression of the glucose transporter gene. J Biol Chem. 1988;263:13655-13662.
28. Mineta H, Miura K, Takebayashi S, et al. Prognostic value of glucose transporter 1 expression in patients with hypopharyngeal carcinoma. Anticancer Res. 2002;22:3489-3494.
29. Younes M, Brown RW, Stephenson M, et al. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer. 1997;80:1046-1051.
30. Kawamura T, Kusakabe T, Sugino T, et al. Expression of glucose transporter- 1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer. 2001;92:634-641.
31. Airley R, Loncaster J, Davidson S, et al. Glucose transporter Glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res. 2001;7:928-934.
32. Kunkel M, Reichert TE, Benz P, et al. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer. 2003;97:1015-1024.
33. Rosenblatt-Velin N, Montessuit C, Papageorgiou I, et al. Post-infarction heart failure in rats is associated with upregulation of GLUT-1 and downregulation of genes of fatty acid metabolism. Cardiovasc Res. 2001;52:407-416.
34. Clavo A, Brown R, Wahl R. 2-fluoro-2-deoxy-D-glucose (FDG) uptake into human cancer cell lines is increased by hypoxia. J Nucl Med. 1995;36:1625-1632.
35. Sivitz WI, Lund DD, Yorek B, et al. Pretranslational regulation of two cardiac glucose transporters in rats exposed to hypobaric hypoxia. Am J Physiol. 1992;263:562-569.
36. Cantuaria G, Magalhaes A, Penalver M, et al. Expression of GLUT-1 glucose transporter in borderline and malignant epithelial tumors of the ovary. Gynecol Oncol. 2000;79:33-37.
37. Kurokawa T, Yoshida Y, Kawahara K, et al. Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer. 2004;109:926-932.
38. Hubner KF, McDonald TW, Niethammer JG, et al. Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[18F]deoxyglucose (2-[18F]FDG). Gynecol Oncol. 1993;51:197-204.
39. Karlan BY, Hawkins R, Hoh C, et al. Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. Gynecol Oncol. 1993;51:175-181.
40. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002;2:683-693.
41. Smith TA. FDG uptake, tumour characteristics and response to therapy: a review. Nucl Med Commun. 1998;19:97-105.
42. Higashi T, Saga T, Nakamoto Y, et al. Relationship between retention index in dual-phase (18)F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med. 2002;43:173-180.
43. Vesselle H, Schmidt RA, Pugsley JM, et al. Lung cancer proliferation correlates with [F-18] fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res. 2000;6:3837-3844.
44. Folpe AL, Lyles RH, Sprouse JT, et al. (F-18) Fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res. 2000;6:1279-1287.
45. Minn H, Lapela M, Klemi PJ, et al. Prediction of survival with fluorine- 18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med. 1997;38:1907-1911.
46. Buck A, Schirrmeister H, Kuhn T, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging. 2002;29:1317-1323.
47. Saga T, Higashi T, Ishimori T, et al. Clinical value of FDG-PET in the follow-up of post-operative patients with endometrial cancer. Ann Nucl Med. 2003;17:197-203.
48. Nakahara T, Fujii H, Ide M. F-18 FDG uptake in endometrial cancer. Clin Nucl Med. 2001;26:82-83.
49. Belhocine T, De Barsy C, Hustinx R, et al. Usefulness of F-FDG PET in the post-therapy surveillance of endometrial carcinoma. Eur J Nucl Med. 2002;29:1132-1139.
50. Cantuaria G, Magalhaes A, Angioli R, et al. Antitumor activity of a novel glyco-nitric oxide conjugate in human ovarian cancer. Cancer. 2000;88:381-388.